Molecular Templates, INC
Market Movers (8-K)
8-K: Molecular Templates Files for Chapter 11 Bankruptcy, Secures DIP Financing from K2 HealthVentures
Molecular Templates, Inc. and its affiliate have filed for Chapter 11 bankruptcy and entered into a restructuring support agreement with K2 HealthVentures, securing debtor-in-possession financing to continue operations.
Capital raise
Molecular Templates enters into a bridge loan agreement for immediate funding and amends its contingent value right agreement to address near-term financial obligations.
Worse than expected
Capital raise
8-K: Molecular Templates Announces Mass Resignation of Board and Executive Team, Initiates Wind-Down
Molecular Templates has announced the resignation of its entire board and executive team, including the CEO, and has initiated a wind-down of its business affairs.
Worse than expected
Molecular Templates, Inc. has received notice from Nasdaq that it is considered a public shell and will be delisted from the exchange.
Worse than expected
Delay expected
Molecular Templates has cancelled its special stockholder meeting due to insufficient shareholder representation to achieve a quorum.
Worse than expected
Delay expected
Molecular Templates' Chief Financial Officer, Jason Kim, has resigned, and CEO Eric Poma will serve as interim CFO.
Quarterly Earnings (10-Q)
Molecular Templates reports a net loss for Q2 2024 and expresses substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
Molecular Templates reports a net income of $572,000 for Q1 2024, while navigating the termination of the Bristol-Myers Squibb collaboration and implementing cost-saving measures.
Capital raise
Worse than expected
Annual Reports (10-K)
10-K/A: Molecular Templates Files Amended 10-K to Include Omitted Information and Updated Certifications
Molecular Templates has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and updated certifications from its CEO and CFO.
Capital raise
Molecular Templates, Inc. outlines its capital structure, ongoing clinical programs, and strategic review process in its latest 10-K filing.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
Biotech Target N.V. and BB Biotech AG jointly filed a Form 4 detailing the sale of common stock and the acquisition of prefunded and common warrants in Molecular Templates, Inc.
Proxy Statements (Def-14A)
Molecular Templates, Inc. has cancelled its special meeting of stockholders due to insufficient proxies to establish a quorum.
Delay expected
Worse than expected
Molecular Templates has adjourned its special stockholder meeting regarding the company's dissolution and liquidation plan to December 4, 2024.
Delay expected
Worse than expected